ARCT 241018 22.50P (ARCT241018P22500) Stock Options, News & Quotes

US OptionsDetailed Quotes

ARCT241018P22500

Watchlist

1.55
-1.55-50.00%

15min DelayClose Oct 1 16:00 ET

1.55High1.55Low

Intraday

5D
Daily

News

Unveiling 3 Analyst Insights On Arcturus Therapeutics
Benzinga17:00 ET
Buy Rating Justified by Arcturus Therapeutics' Market Potential and Strong Vaccine Efficacy
TipRanks12:35 ET · Ratings
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $63
Moomoo News12:32 ET · Ratings
Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.
Dow Jones12:22 ET · Ratings
Wells Fargo Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $58
Moomoo NewsOct 1 05:31 ET · Ratings
Express News | Self-Amplifying Mrna Covid-19 Vaccine Demonstrates Superior Immune Response Compared With Mrna Vaccine at 12 Months Post-Vaccination
ReutersSep 30 08:00 ET

Comments

Laurence john tawil

May 28 23:16

$Arcturus Therapeutics (ARCT.US)$ wtf is happening bout to put this hoe down

Moomoo AI

Mar 9 20:57

Analysts maintain loss per share estimates for next year with no major changes to revenue estimates. However, the company's performance is expected to underperform the wider industry. The steady consensus price target indicates that reduced loss estimates may not positively impact the stock's long-term valuation.

Analysts Have Made A Financial Statement On Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Yearly Report

Moomoo AI

Feb 28 20:46

Despite Arcturus Therapeutics Holdings Inc.'s strong run, its P/S ratio remains low due to a weak revenue outlook. Investors believe the potential for revenue improvement doesn't justify a higher P/S ratio, forming a barrier for the share price.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

FlexibleTrader

Feb 10 02:29

$Arcturus Therapeutics (ARCT.US)$ in game 👀✈️

Moomoo AI

Feb 7 02:49

The recent improvement in total shareholder return could indicate that the business is getting better over time. However, there are 2 warning signs that investors should be aware of. The sentiment around the company seems to be positive lately.

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Delivers Shareholders Incredible 48% CAGR Over 5 Years, Surging 7.2% in the Last Week Alone